Hikal
HIKAL · Pharma > Pharmaceuticals & Drugs · Chairman: Jai Hiremath · MD: Jai Hiremath · Listing date: Feb. 15, 2001 · Employees: 1528 · Navi Mumbai · http://www.hikal.com

Stock Price vs Company Growth
1d
2.2%
1w
4.7%
1m
18.7%
3m
30.6%
6m
36.2%
1y
59.3%
5y
3.2%
10y
7.8%
all
7.5%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 166 2.2%
155
233
Company Overview

Sales
1,746 Cr
Growth: -8.9%
Profit after Tax
-13 Cr
Growth: -228.7%
Small Cap
2,041 Cr
P/S: 1.2x
Industry P/S: 2.0x
Fundamentals

Sales (Cr) ₹ 1,746
Growth -8.9%
EBITDA 13.7%
P/S 1.2x
Dividend 0.3%
P/E -156.2x
Book Value ₹ 97.3
PEG Ratio 17.6x
ROE -1.1%
P/B 1.7x
Shareholding Pattern

Institutions
Government Pension Fund Global
2.31 %
Promoters
Kalyani Investment Company Limited
31.36 %
Shri Badrinath Investment Pvt Ltd
16.15 %
Shri Rameshwara Investment Pvt Ltd
7.96 %
Sugandha Jai Hiremath
7.84 %
Bf Investment Limited
2.65 %
Others
Si Investments And Broking Private Limited
1.62 %
Llp
0.4 %
Iepf
0.21 %
Increase    Decrease    No change
Company Profile Detailed

Established in 1988 Hikal is a reliable partner to companies in the Pharmaceuticals, Biotech, Agrochemicals and Specialty Chemicals industries. They provide world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner. Their advanced infrastructure has been inspected and approved by globally recognized bodies such as the USFDA. Hikal is a company built on enduring relationships.
Investors (65)
Followers (6)